Elanco Animal Health Inc, founded in 1954 and headquartered in Greenfield, Indiana, is a global leader in animal health focused on innovating solutions that enhance animal health and performance. The company offers a comprehensive portfolio of products, including vaccines, parasiticides, and antimicrobial treatments, aimed at promoting the health of pets and livestock.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| ELAN 4.90% 2028-08-28 USDElanco Animal Health Inc | United States | 2028-08-28 | 4.900 | 5.16 |
| ELAN 4.90% 2028-08-28 USDElanco Animal Health Inc | United States | 2028-08-28 | 4.900 | 5.16 |
| ELAN 6.65% 2028-08-28 USDElanco Animal Health Inc | United States | 2028-08-28 | 6.650 | 5.09 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Elanco has a history of bond issuances that began in the early 2000s to support its growth strategy and acquisitions. Notably, in 2020, Elanco issued $2 billion in senior notes to finance the acquisition of Bayer's animal health business, which significantly expanded its market presence. Current yields on Elanco's bonds reflect a competitive position within the animal health sector, with features that include callable options, providing flexibility amid changing market conditions. With consistent updates on their bond performance and strategic objectives, Elanco maintains investor interest as it navigates the evolving landscape of animal health.